5.2 Digoxin and Cardiac Glycosides: Mechanism, Arrhythmias, and Digoxin Immune Fab

Cardiac glycosides have been utilized in clinical medicine for over two centuries, originating from William Withering's classic 1785 treatise on the purple foxglove (Digitalis purpurea). Today, digoxin remains the primary pharmaceutical cardiac glycoside used for rate control in atrial fibrillation and symptom reduction in heart failure with reduced ejection fraction. In addition to pharmaceutical digoxin and digitoxin, cardiac glycosides are naturally occurring xenobiotics found in numerous toxic plants—including Digitalis purpurea and Digitalis lanata (foxglove), Nerium oleander (common oleander), Thevetia peruviana (yellow oleander), Convallaria majalis (lily of the valley), and Asclepias species (milkweed)—as well as toad secretions from the genus Bufo (bufadienolides). Because of digoxin's exceptionally narrow therapeutic index (0.5 to 0.9 ng/mL for heart failure; 0.8 to 2.0 ng/mL for rate control) and widespread use in frail, elderly populations with fluctuating renal function, both acute intentional overdoses and chronic insidious toxicities are frequently managed by poison centers.

---

Cellular Mechanism of Action and Electrophysiology

Digoxin binds specifically and reversibly to the extracellular phosphorylation site on the alpha-subunit of the myocardial cell membrane sodium-potassium adenosine triphosphatase (Na+/K+-ATPase) pump. Under normal basal conditions, this active transport pump hydrolyzes ATP to extrude 3 intracellular Na+ ions in exchange for 2 extracellular K+ ions, maintaining the negative resting membrane potential and trans-sarcolemmal chemical gradients.

Normal Myocyte Function:
3 Na+ Extruded / 2 K+ Imported via Na+/K+-ATPase → Forward NCX Extrudes 1 Ca2+ / Imports 3 Na+

Digoxin Toxicity Cascade:
Na+/K+-ATPase Inhibited → Intracellular [Na+] Rises → Trans-sarcolemmal Na+ Gradient Collapses
                                                                          ↓
              NCX Impaired / Reversed (Cannot Extrude Ca2+) ← [NCX Gradient Eliminated]
                                                                          ↓
                 Intracellular [Ca2+] Surges → Sarcoplasmic Reticulum Ca2+ Overload
                                                                          ↓
           Diastolic Spontaneous Ca2+ Oscillations → Delayed Afterdepolarizations (DADs)
                                                                          ↓
      Triggered Ventricular Ectopy, Bigeminy, Bidirectional VT, and Ventricular Fibrillation

Inotropy vs. Arrhythmogenesis

1. Inotropic Effect: Inhibition of the Na+/K+-ATPase pump leads to progressive accumulation of intracellular sodium ([Na+]i). The resulting dissipation of the trans-sarcolemmal sodium chemical gradient impairs or reverses the forward-mode function of the sodium-calcium exchanger (NCX), which normally extrudes calcium against its electrochemical gradient. Consequently, intracellular calcium ([Ca2+]i) accumulates and is pumped into the sarcoplasmic reticulum (SR) by the SERCA2a pump. During subsequent action potentials, the augmented SR calcium release provides increased free calcium to troponin C, enhancing myocardial contractility.
2. Electrophysiological Toxicity and Delayed Afterdepolarizations (DADs): When intracellular and SR calcium stores exceed storage capacity, spontaneous calcium oscillations escape into the cytoplasm during Phase 4 diastole. This cytoplasmic calcium surge activates transient inward currents (Iti, primarily mediated by electrogenic NCX exchanging 1 Ca2+ for 3 Na+), generating delayed afterdepolarizations (DADs). When DADs reach the threshold potential of voltage-gated sodium channels, they fire premature action potentials, producing triggered automaticity. This is the fundamental electrophysiological mechanism underlying digitalis-induced premature ventricular contractions (PVCs), ventricular bigeminy, fascicular tachycardias, and bidirectional ventricular tachycardia.
3. Autonomic / Vagal Effects: Concurrently, digoxin exerts potent neurohormonal actions. It stimulates central vagal nuclei in the medulla and sensitizes peripheral baroreceptors, increasing postganglionic parasympathetic acetylcholine release at muscarinic M2 receptors in the sinoatrial (SA) and atrioventricular (AV) nodes. This prolongs nodal refractory periods and decreases conduction velocity, producing sinus bradycardia, SA block, PR prolongation, and high-grade AV block.

---

Electrocardiographic Hallmarks: Therapeutic Effect vs. Toxic Arrhythmias

A paramount principle in clinical toxicology is distinguishing benign, therapeutic digitalis exposure from life-threatening digitalis cardiotoxicity.

Digitalis Effect (Non-Toxic)

Therapeutic digoxin concentrations produce characteristic repolarization changes on the 12-lead ECG, collectively termed the "digitalis effect". These changes reflect shortened ventricular action potential duration and altered Phase 1/2 repolarization:

• ST-Segment Depression with "Scooped" Morphology: A distinctive, sagging, concave ST-segment depression resembling the curved curve of a Salvador Dalí mustache, most prominent in leads with tall R waves (V4–V6, I, aVL).
• T-Wave Flattening or Inversion: Often biphasic with a terminal negative deflection.
• Shortened QT/QTc Interval: Due to accelerated Phase 2/3 repolarization.
• Mild PR Interval Prolongation: Typically 200 to 240 ms due to enhanced vagal tone.
• Crucial Rule: Digitalis effect is NOT an indicator of toxicity or an indication for Digoxin Immune Fab. It merely confirms that the patient is taking a cardiac glycoside.

Toxic Digoxin Dysrhythmias

Digoxin toxicity can provoke almost any known cardiac dysrhythmia. However, because it simultaneously increases ventricular and junctional automaticity while depressing SA and AV nodal conduction, specific dysrhythmias are highly characteristic and pathognomonic:

---

Acute vs. Chronic Toxicity: Two Distinct Clinical Entities

The presentation, diagnostic evaluation, prognostic markers, and management priorities of digitalis poisoning depend entirely on whether the exposure is acute or chronic.

Acute Overdose (Single Massive Ingestion):
Normal Renal Function → Rapid Onset (1-6 h) → Severe GI Distress → Intact Vision
HALLMARK: Hyperkalemia (K+ >5.0 mEq/L) from Whole-Body Na+/K+-ATPase Shutdown → Drives Mortality

Chronic Overdose (Accumulation in Renal Failure / Drug Interactions):
Impaired GFR / Diuretics → Insidious (Days-Weeks) → Neuro-Ophthalmic Symptoms (Xanthopsia, Delirium)
HALLMARK: Hypokalemia / Hypomagnesemia Sensitizes Myocardium → Ventricular Arrhythmias at Lower Digoxin Levels

The Bismuth Criteria and Potassium as a Prognostic Biomarker

In acute digitalis poisoning, massive systemic inhibition of the Na+/K+-ATPase pump affects not only the myocardium, but the entire skeletal muscle bed (which contains the largest physiological reservoir of Na+/K+-ATPase pumps in the human body). When skeletal muscle pumps are inactivated, myocytes cannot transport potassium back into the intracellular compartment, causing extracellular potassium to surge rapidly into the circulation.

In their landmark clinical study, Bismuth and colleagues demonstrated that in acute digoxin overdose, serum potassium concentration is the single most accurate prognostic indicator of mortality, far outperforming the serum digoxin concentration itself:

• Initial Serum K+ < 5.0 mEq/L: Correlates with approximately 0% mortality.
• Initial Serum K+ 5.0 to 5.5 mEq/L: Correlates with approximately 50% mortality without antidotal therapy.
• Initial Serum K+ > 5.5 mEq/L: Correlates with nearly 100% mortality in the absence of Digoxin Immune Fab administration.

Consequently, in an acute cardiac glycoside overdose, a serum potassium > 5.0 mEq/L is an independent, absolute indication for Digoxin Immune Fab.

Sensitizing Factors in Chronic Toxicity

In chronic toxicity, patients are frequently hypokalemic and hypomagnesemic due to concurrent loop or thiazide diuretic therapy. Potassium and digoxin compete for the identical extracellular binding domain on the Na+/K+-ATPase pump. When serum potassium is depressed, competitive displacement is eliminated, allowing digoxin molecules to bind more avidly and persistently to the pump. Thus, hypokalemia dramatically potentiates digitalis cardiotoxicity, precipitating life-threatening dysrhythmias at serum digoxin levels that appear only modestly elevated (e.g., 1.5 to 2.2 ng/mL). Hypomagnesemia similarly destabilizes the resting membrane potential and exacerbates intracellular calcium loading.

---

Digoxin Immune Fab (DigFab): Indications, Mechanism, and Dosing Calculations

Digoxin Immune Fab (ovine-derived, trade name DigiFab) is the definitive, life-saving antidote for cardiac glycoside poisoning. It consists of purified, papain-cleaved Fab (antigen-binding fragment) immunoglobulin fragments (~46 kDa) obtained from sheep hyperimmunized with a digoxin-albumin conjugate. Because the Fc constant region is cleaved and removed, Fab fragments exhibit low immunogenicity, rapid tissue distribution, and rapid renal elimination.

Mechanism of Action

Fab fragments possess an affinity for digoxin (Ka approximately 10^9 to 10^10 M^-1) that is 20 to 100 times greater than the affinity of myocardial Na+/K+-ATPase for digoxin. Following IV administration, Fab rapidly binds to free digoxin in the intravascular space. This creates a steep concentration gradient, pulling tissue-bound digoxin off myocardial receptor sites into the vascular space, where it is bound and neutralized. The resulting inactive, hydrophilic Fab-digoxin complex is eliminated via glomerular filtration.

Clinical Indications for Digoxin Immune Fab

1. Cardiac Arrest or Peri-Arrest: Any cardiac arrest in a patient with suspected or confirmed cardiac glycoside toxicity.
2. Life-Threatening Dysrhythmias: Ventricular tachycardia, ventricular fibrillation, bidirectional VT, or rapid unstable ectopy.
3. Hemodynamically Unstable Bradyarrhythmias: Severe sinus bradycardia, high-grade AV block, or sinus arrest unresponsive to atropine (0.5 to 1 mg IV).
4. Acute Ingestion Thresholds: Ingestion of >10 mg of digoxin in an adult, or >4 mg (or >0.1 mg/kg) in a child.
5. Serum Digoxin Concentration Thresholds: Steady-state concentration >10 to 15 ng/mL in acute poisoning, or >2.5 to 3.0 ng/mL in chronic poisoning with progressive toxicity.
6. Acute Poisoning Hyperkalemia: Serum potassium >5.0 mEq/L in the setting of acute digitalis toxicity.

Stoichiometric Calculations: The 0.5 mg Neutralization Principle

Each 40-mg vial of Digoxin Immune Fab neutralizes approximately 0.5 mg (500 mcg) of digoxin (or digitoxin). Dosing can be calculated accurately using either of two established methods.

Method 1: Known Ingested Dose Method

When the acute ingested quantity is known with reasonable certainty, calculate the total bioavailable dose. Because standard digoxin commercial tablets have an oral bioavailability of approximately 80% (0.8), the bioavailable amount is multiplied by 0.8:

Number of Vials = (Ingested Dose in mg * 0.8) / 0.5 mg/vial

For an IV overdose (100% bioavailable):
Number of Vials = Ingested Dose in mg / 0.5 mg/vial

Example Calculation: A patient swallows forty 0.25-mg digoxin tablets (total ingested mass = 10 mg). The bioavailable dose is 10 mg * 0.8 = 8 mg. The required dose is 8 mg / 0.5 mg/vial = 16 vials.

Method 2: Steady-State Serum Concentration Method

When the ingested dose is unknown but a steady-state serum digoxin concentration (Cp in ng/mL) and patient body weight (kg) are available, total body burden is estimated using digoxin's steady-state volume of distribution (Vd approximately 5.6 L/kg):

Total Body Burden (mg) = (Serum Digoxin in ng/mL * 5.6 L/kg * Weight in kg) / 1000

Clinical Bedside Formula:
Number of Vials = (Serum Digoxin Concentration in ng/mL * Patient Weight in kg) / 100

Note on Timing: The serum digoxin level must be drawn at steady state—at least 6 to 8 hours post-ingestion in acute overdose. Levels drawn within the initial 1 to 4 hours reflect incomplete distribution (Vd still contracting), yielding falsely elevated serum levels that drastically overestimate vial requirements.

Example Calculation: An 80-kg male with chronic toxicity has a steady-state serum digoxin level of 7.5 ng/mL. Number of vials = (7.5 * 80) / 100 = 600 / 100 = 6 vials.

Empiric Dosing Strategy

When immediate laboratory concentrations or precise ingestion quantities are unavailable and the patient is unstable:

• Acute Poisoning with Cardiac Arrest or Hemodynamic Collapse: Administer 10 to 20 vials IV push. (10 vials neutralizes 5 mg of bioavailable drug, covering most adult ingestions; 20 vials neutralizes 10 mg, covering virtually all lethal overdoses).
• Chronic Toxicity with Unstable Dysrhythmias or Heart Block: Administer 3 to 6 vials IV infusion over 30 minutes. In chronic toxicity, total body accumulation rarely exceeds 1 to 2 mg; 3 to 6 vials provides complete neutralization without excessively exhausting hospital antidote supplies.

---

Post-Fab Pharmacokinetics and Clinical Monitoring Pitfalls

Administering Digoxin Immune Fab creates an immediate and dramatic pharmacokinetic shift that every poison specialist must anticipate.

The Immunoassay Interference Pitfall: Invalidation of Total Digoxin Levels

Standard clinical hospital laboratories utilize automated, commercial total digoxin immunoassays (e.g., chemiluminescent or enzyme-multiplied immunoassay techniques [EMIT]). These antibody-based assays are designed to detect the digoxin steroid core.

Pre-Fab State:  [Free Active Digoxin = Toxic (e.g., 6.0 ng/mL)] → Measured Level: 6.0 ng/mL
                        ↓ (Administer Digoxin Immune Fab)
Post-Fab State: [Free Active Digoxin = 0 ng/mL (Non-Toxic)]
                [Fab-Bound Digoxin Complex Surges in Vascular Space]
                        ↓ (Immunoassay cross-reacts with Bound Complex)
Reported Total Level: 60.0 to 120.0 ng/mL! (Falsely Skyrockets 10- to 100-Fold!)

Within minutes of Fab administration, free active digoxin falls to zero. However, the inactive Fab-digoxin complex remains in the intravascular space while awaiting renal filtration. Routine clinical immunoassays cannot distinguish between free active digoxin and inactive Fab-bound digoxin. As a result, the reported "total digoxin concentration" falsely surges 10- to 100-fold (often reading >20 to >100 ng/mL).

Poison Center Golden Rule: Never order, monitor, or make clinical decisions based on serum digoxin concentrations following Digoxin Immune Fab administration. Post-Fab total levels are completely uninterpretable and remain confounded for 1 to 2 weeks (or longer in patients with renal failure). Only specialized research laboratories capable of ultrafiltration to separate free from bound drug can measure free levels.

Clinical and Laboratory Monitoring Following Fab

Resuscitation endpoints must rely strictly on clinical and electrophysiological parameters:

1. Continuous Telemetry: Reversal of nodal conduction block and cessation of ventricular ectopy typically begins within 15 to 30 minutes, with complete resolution achieved by 60 to 90 minutes.
2. Serial Serum Potassium Monitoring: As the Na+/K+-ATPase pumps are freed from digoxin inhibition, skeletal muscle cells immediately begin pumping extracellular potassium back into the intracellular compartment. In acute overdoses with hyperkalemia, serum potassium drops rapidly (often by 1.5 to 3.0 mEq/L within 1 to 2 hours). Clinicians must monitor potassium hourly to avoid sudden precipitous hypokalemia.
3. Renal Failure and Delayed Dissociation: In patients with end-stage renal disease (ESRD), Fab-digoxin complexes cannot be cleared by glomerular filtration. The half-life of the complex extends from 16–24 hours to over 100 hours. Although rare, slow dissociation of the complex can theoretically release free digoxin after 48 to 72 hours, producing recurrent toxicity. Prolonged telemetry observation (48 to 72 hours) is indicated in dialysis patients.

The Intravenous Calcium Controversy: The "Stone Heart" Myth

Historical medical dogma warned that administering intravenous calcium in digoxin-poisoned patients precipitated irreversible, tetanic myocardial contracture in diastole (the so-called "stone heart"). Modern retrospective toxicology reviews and porcine animal models have demonstrated that therapeutic doses of IV calcium do not cause instantaneous cardiac arrest. However, because hypercalcemia worsens intracellular calcium overload and potentiates delayed afterdepolarizations, and because Digoxin Immune Fab is the specific, definitive antidote, intravenous calcium is generally avoided in digitalis cardiotoxicity.

If severe hyperkalemia (K+ >6.0 mEq/L) with widening QRS complexes is present, the treatment of choice is immediate Digoxin Immune Fab, which resolves hyperkalemia by reactivating the cell-membrane pump. Adjunctive measures like insulin/dextrose and sodium bicarbonate may be used with caution, while calcium should be withheld unless refractory arrest occurs and Fab is completely unavailable.

---

Clinical Poison Center Case Scenario: The CKD Patient with "Yellow Snow"

An 82-year-old female weighing 50 kg with a history of permanent atrial fibrillation and stage 4 chronic kidney disease is brought to the emergency department after 4 days of progressive lethargy, confusion, nausea, and decreased oral intake. Her daughter notes the patient complained that the outdoor snow looked "bright yellowish-green." Her current home medications include digoxin 0.125 mg daily and furosemide 40 mg daily. On arrival, her blood pressure is 88/44 mmHg, heart rate is 42 bpm, and telemetry reveals slow atrial fibrillation with a strictly regularized ventricular response at 42 bpm (complete heart block with junctional escape). Laboratory evaluation reveals: potassium 3.1 mEq/L, BUN 68 mg/dL, serum creatinine 3.8 mg/dL (baseline 1.8), and a serum digoxin concentration of 5.8 ng/mL.

Poison Specialist Assessment and Antidote Plan

1. Recognition: The combination of insidious onset, confusion, visual disturbances (xanthopsia), slow AF with a regularized escape rhythm, and elevated digoxin in the setting of acute-on-chronic renal failure confirms severe chronic digitalis toxicity. The concurrent hypokalemia (3.1 mEq/L) exacerbates cardiotoxicity.
2. Dose Calculation: Using the serum level method: Vials = (5.8 ng/mL * 50 kg) / 100 = 290 / 100 = 2.9 -> 3 vials of Digoxin Immune Fab.
3. Administration: 3 vials of DigFab are reconstituted and infused over 30 minutes.
4. Telemetry and Potassium Course: At 45 minutes post-infusion, telemetry converts from regularized complete heart block back to normal, irregular atrial fibrillation with a ventricular rate of 78 bpm. Blood pressure rises to 118/70 mmHg. Potassium is cautiously repleted with 20 mEq oral KCl.
5. Post-Fab Trap Avoidance: The attending physician considers drawing a repeat digoxin level at 4 hours. The CSPI intervenes, explaining that post-Fab immunoassays measure inactive Fab-bound complex and will falsely read >30 ng/mL, providing zero useful clinical data. Serial telemetry and potassium monitoring guide successful discharge 3 days later.